BerGenBio ASA

BerGenBio ASA is a clinical-stage biopharmaceutical company dedicated to developing innovative drugs for aggressive diseases. Focusing on first-in-class selective AXL kinase inhibitors, BerGenBio ASA aims to create novel therapeutic options for cancer patients. The company is at the forefront of understanding the critical role of AXL kinase in promoting cancer spread, immune evasion, and drug resistance, which is a major cause of cancer-related deaths.

Located at Jonas Lies vei 91, Bergen, Norway, and with an additional location at 1 Robert Robinson Ave, Oxford, Oxfordshire OX44GA, GB, BerGenBio ASA is committed to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness. Through pioneering research and development, BerGenBio ASA strives to improve patient outcomes and transform the landscape of cancer treatment.

BerGenBio ASA’s efforts are directed toward providing effective solutions in oncology and beyond. The company's innovative approach offers hope for those affected by drug-resistant cancers. We invite the manager of BerGenBio ASA to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.